On Tuesday, Tscan Therapeutics Inc (NASDAQ: TCRX) opened higher 15.86% from the last session, before settling in for the closing price of $1.45. Price fluctuations for TCRX have ranged from $1.02 to $7.89 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -14.41% over the past five years. Company’s average yearly earnings per share was noted -10.90% at the time writing. With a float of $43.83 million, this company’s outstanding shares have now reached $52.31 million.
Let’s look at the performance matrix of the company that is accounted for 194 employees. In terms of profitability, gross margin is 58.67%, operating margin of -3159.87%, and the pretax margin is -2974.08%.
Tscan Therapeutics Inc (TCRX) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Tscan Therapeutics Inc is 22.56%, while institutional ownership is 71.46%. The most recent insider transaction that took place on May 19 ’25, was worth 1,666,553. In this transaction 10% Owner of this company bought 1,388,794 shares at a rate of $1.20, taking the stock ownership to the 6,746,141 shares. Before that another transaction happened on May 20 ’25, when Company’s 10% Owner bought 1,200,000 for $1.20, making the entire transaction worth $1,440,000. This insider now owns 7,946,141 shares in total.
Tscan Therapeutics Inc (TCRX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around -10.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.18% during the next five years compared to -14.41% drop over the previous five years of trading.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Check out the current performance indicators for Tscan Therapeutics Inc (TCRX). In the past quarter, the stock posted a quick ratio of 8.55. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.51.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.09, a number that is poised to hit -0.33 in the next quarter and is forecasted to reach -1.18 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Tscan Therapeutics Inc (NASDAQ: TCRX) saw its 5-day average volume 0.45 million, a negative change from its year-to-date volume of 0.48 million. As of the previous 9 days, the stock’s Stochastic %D was 31.91%.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 40.00%, which indicates a significant decrease from 60.59% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.98% in the past 14 days, which was lower than the 89.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.4815, while its 200-day Moving Average is $3.0085. Nevertheless, the first resistance level for the watch stands at $1.7867 in the near term. At $1.8933, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.0567. If the price goes on to break the first support level at $1.5167, it is likely to go to the next support level at $1.3533. Assuming the price breaks the second support level, the third support level stands at $1.2467.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
There are currently 56,591K shares outstanding in the company with a market cap of 95.08 million. Presently, the company’s annual sales total 2,820 K according to its annual income of -127,500 K. Last quarter, the company’s sales amounted to 2,170 K and its income totaled -34,130 K.
